G. Chouinard

Publications305
h-index56
Citations12,929
Highly Influential Citations374
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • G. Fava
  • 592 Publications • 19,819 Citations
  • L. Annable
  • 117 Publications • 3,911 Citations
  • D. Greenblatt
  • 1,360 Publications • 62,153 Citations
  • R. Shader
  • 893 Publications • 27,170 Citations
  • Publications
  • Influence
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
View on Elsevier
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
TLDR
The large between-group differences on negative symptoms, hostility/excitement, and anxiety/depression suggest that risperidone and other serotonin/dopamine antagonists have qualitatively different effects from those of conventional antipsychotic agents.
View on PubMed
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
TLDR
It is suggested that clozapine therapy significantly reduces suicidal behavior in patients with schizophrenia and schizoaffective disorder at high risk for suicide, and use of clozAPine in this population should lead to a significant reduction in suicidal behavior.
View on PubMed
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
TLDR
It is suggested that risperidone, at the optimal therapeutic dose of 6 mg/day, produced significant improvement in both positive and negative symptoms without an increase in drug-induced parkinsonian symptoms and with a significant beneficial effect on tardive dyskinesia.
View on PubMed
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
  • G. Chouinard
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1 March 2004
TLDR
Although as a class benzodiazepines act rapidly and are well tolerated, their use presents clinical issues such as dependence, rebound anxiety, memory impairment, and discontinuation syndrome.
View on PubMed
Severe cases of neuroleptic-induced supersensitivity psychosis Diagnostic criteria for the disorder and its treatment
  • G. Chouinard
  • Psychology, Medicine
    Schizophrenia Research
  • 1 July 1991
View on Elsevier
Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.
TLDR
Results support the safety and efficacy of daily dosages of 50, 100, and 200 mg of sertraline in the short-term treatment of patients with OCD.
View on PubMed
Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia
View on Elsevier
Neuroleptic-induced supersensitivity psychosis.
TLDR
The anticholinergic effects of chlorpromazine, amitriptyline, scopolamine (Sominex) (0), and tropicamide were probably additive and although her disorientation cleared rapidly, Ms. A maintained that her hallucinations persisted during her 2-week hospitalization.
View on PubMed
Risperidone in the Treatment of Tourette Syndrome: A Double-Blind, Placebo-Controlled Trial
TLDR
Treatment with risperidone was accompanied by an improvement in global functioning in patients with average to above-average impairment at baseline as measured by the Global Assessment of Functioning scale, and hypokinesia and tremor increased in the ris peridone group, but the effect on tremor was largely confined to subjects with higher baseline tremor scores.
View on Wolters Kluwer
...
...